Compound Evidence File
#EC-2026-0626
Tamoxifen (Nolvadex) Raw
Filed under Raw Materials. The bureau holds 101 laboratory returns for this compound from 31 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
31 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 6 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 10.0 | 10.0 | 10.0 | 7 Nov 2025 | 7 Jul 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 10.0 | 9.9 | 10.0 | 10 Apr 2026 | 1 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 10.0 | 9.9 | 10.0 | 22 Apr 2026 | 24 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 19 Feb 2026 | 21 Jun 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 22 Nov 2025 | 1 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 8 Mar 2026 | 23 Mar 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 10.0 | 10.0 | 10.0 | 27 Jan 2026 | 17 Mar 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 20 Feb 2026 | 21 Jun 2026 |
| Trusted PeptideCASE #VI-2026-0499 | X | 1 | 10.0 | 10.0 | 10.0 | 7 May 2025 | 7 May 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 4 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 9.9 | 9.9 | 10.0 | 12 Dec 2025 | 3 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 10 Jun 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 27 Feb 2026 | 22 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 9.9 | 7 Mar 2026 | 22 Mar 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 10 Apr 2026 | 25 Jun 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 9.3 | 8.7 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 8 | 9.0 | 7.9 | 9.7 | 25 May 2026 | 25 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.5 | 7.3 | 9.6 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 8 | 8.5 | 6.4 | 10.0 | 21 May 2026 | 21 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 8 | 8.2 | 6.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Heman Peptide HMCASE #VI-2026-0089 | X | 1 | 8.1 | 8.1 | 8.1 | 11 Jun 2025 | 11 Jun 2025 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 7.9 | 7.9 | 7.9 | 2 Jul 2025 | 2 Jul 2025 |
| Verified PeptidesCASE #VI-2026-0407 | X | 2 | 7.8 | 6.3 | 9.3 | 25 Apr 2025 | 17 May 2026 |
| Hebei Rimao TechnologyCASE #VI-2026-0529 | X | 3 | 7.6 | 6.9 | 8.2 | 2 Jul 2025 | 21 May 2026 |
| ScienceCASE #VI-2026-0636 | X | 1 | 7.4 | 7.4 | 7.4 | 28 Mar 2025 | 28 Mar 2025 |
| Yongkang Nuoao Trading CoCASE #VI-2026-0646 | X | 1 | 7.4 | 7.4 | 7.4 | 2 Apr 2025 | 2 Apr 2025 |
| LN PeptidesCASE #VI-2026-0781 | X | 2 | 6.2 | 5.4 | 7.0 | 28 Mar 2025 | 25 May 2026 |
| Quenna PMQCASE #VI-2026-0415 | X | 1 | 5.6 | 5.6 | 5.6 | 25 Apr 2025 | 25 Apr 2025 |
| TydesCASE #VI-2026-0493 | X | 4 | 5.0 | 4.2 | 5.5 | 2 Jul 2025 | 26 Jan 2026 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | X | 1 | 4.3 | 4.3 | 4.3 | 20 Jun 2025 | 20 Jun 2025 |
Open any subject to view the batch-level evidence for Tamoxifen (Nolvadex) Raw alone.